atorvastatin has been researched along with Graft Occlusion, Vascular in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Abreu, AM; Boronat, V; Kulik, A; Ruel, M | 3 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Ezhov, MV; Il'ina, LN; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS | 1 |
| Asif, A; Duque, JC; Escobar, LA; Fayad, F; Martinez, L; Salman, LH; Tabbara, M; Vazquez-Padron, RI | 1 |
| Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S | 1 |
| Huang, MQ; Li, XX; Liu, DY; Lu, WM; Wang, SM; Yu, JX; Zhu, YF | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Atanesyan, RV; Ezhov, MV; Il'ina, LN; Konovalov, GA; Pokrovsky, SN; Safarova, MS | 1 |
| Shechter, M | 1 |
| Barter, P; Breazna, A; DeMicco, DA; Kastelein, JJ; LaRosa, JC; Shah, SJ; Shepherd, J; Waters, DD; Wenger, NK | 1 |
7 trial(s) available for atorvastatin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Impact of lipid levels and high-intensity statins on vein graft patency after CABG: Midterm results of the ACTIVE trial.
Topics: Atorvastatin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Saphenous Vein; Treatment Outcome; Vascular Patency | 2020 |
Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: Rationale and design of the ACTIVE (Aggressive Cholesterol Therapy to Inhibit Vein Graft Events) randomized controlled trial (NCT01528709).
Topics: Aged; Atorvastatin; Cholesterol; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Saphenous Vein; Treatment Outcome; Vascular Patency | 2017 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoprotein(a); Male; Middle Aged; Plasmapheresis; Prospective Studies; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft Events randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Saphenous Vein | 2019 |
Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Russia; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Female; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
4 other study(ies) available for atorvastatin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Distinct impact of three different statins on arteriovenous fistula outcomes: a retrospective analysis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Atorvastatin; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Time Factors; Treatment Failure; Vascular Patency | 2016 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; Carotid Stenosis; Clopidogrel; Disease Models, Animal; Ethanolamines; Graft Occlusion, Vascular; Heptanoic Acids; Hyperplasia; Jugular Veins; Male; Nebivolol; Pyrroles; Rabbits; Ticlopidine; Tunica Intima; Vascular Surgical Procedures | 2009 |
Intensive statin therapy: a favorable adjunct to the improvement of small-diameter vascular grafts.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atorvastatin; Blood Vessel Prosthesis; Cell Adhesion; Cell Movement; Dogs; Endothelial Cells; Endothelium, Vascular; Graft Occlusion, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron, Scanning; Nitric Oxide Synthase; Polytetrafluoroethylene; Postoperative Care; Prosthesis Design; Prosthesis Fitting; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor Receptor-2; Vascular Patency | 2010 |
Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation.
Topics: Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |